Simvastatin decreases myocardial tumor necrosis factor α content in heart transplant recipients

Journal of Heart and Lung Transplantation

Volumn 24, Issue 1, 2005, Pages 46-51

  Wallace, Cynthia K ^e   Stetson, Sonny J ^a,c,d,e   Küçüker, Seref A ^b   Becker, Katy A ^a,c,d,e   Farmer, John A ^a,c   McRee, Susan C ^a,c,d,e   Koerner, Michael M ^a,c,d,e   Noon, George P ^b   Torre Amione, Guillermo ^a,c,d,e  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Section of Cardiology   (United States)

^c Gene and Judy Campbell Lab for Cardiac Transplant Research   (United States)

^d Winters Ctr for Heart Failure Res   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GRAFT SURVIVAL; HEART GRAFT; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY; MALE; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; SIMVASTATIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11844275243     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.09.037     Document Type: Article

References (21)

1. Kobashigawa J.A., Katznelson W., Laks H., et al. Effects of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627
2. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1998;1398-1402
3. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation 8-year prospective experience. Circulation. 107:2003;93-97
4. Cutts J.L., Scallen T.J., Watson J., Bankhurst A.D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol. 139:1989;550-557
5. Cuthbert J.A., Lipsky P.E. Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. J Biol Chem. 265:1990;18568-18575
6. Owens D., Collins P., Johnson A., Tomkin G. Cellular cholesterol metabolism in mitogen-stimulated lymphocytes - requirement for de novo synthesis. Biochim Biophys Acta. 1051:1990;138-143
7. Rezaie-Majd A., Prager G.W., Bucek R.A., et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 23:2003;397-403
8. Calabresi L., Rossoni G., Gomaraschi M., et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release. Circ Res. 92:2003;330-337
9. Cipollone F., Fazia M., Iezzi A., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 107:2003;1479-1485
10. Holm T., Andreassen A.K., Ueland T., et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 87:2001;815-818. A9
11. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure Recognizing the role of proinflammatory cytokines. Chest. 105:1994;897-904
12. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor a and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711
13. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction A report from the studies of left ventricular dysfunction (solvd). J Am Coll Cardiol. 27:1996;1201-1206
14. Stetson S.J., Perez-Verdia A., Mazur W., et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation. 104:2001;676-681
15. Puchtler H., Waldrop F.S., Valentine L.S. Polarization microscopic studies of connective tissue stained with picro-sirius red FBA. Beitr Pathol. 150:1973;174-187
16. Puchtler H., Meloan S.N., Waldrop F.S. Are picro-dye reactions for collagens quantitative? Chemical and histochemical considerations. Histochemistry. 88:1988;243-256
17. Sweat F., Puchtler H., Rosenthal S.I. Sirius Red F3B as stain for connective tissue. Arch Pathol. 78:1964;69-72
18. st ed:1993;Churchill Livingstone, Edinburgh
19. Matsuo T., Mori H., Nishimura Y., et al. Quantification of immunohistochemistry using an image analyzer Correlation with hormone concentrations in pituitary adenomas. Histochem J. 27:1995;989-996
20. Dichtl W., Dulak J., Frick M., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 23:2003;58-63
21. Bays H.E., Stein E.A., Shah A.K., Maccubbin D.L., Mitchel Y.B., Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipdemic and hypertriglyceridemic patients. Am J Cardiol. 90:2002;942-946